中生北控BioSino品牌怎么样 申请店铺

我要投票 中生北控BioSino在基因检测行业中的票数:345 更新时间:2025-07-31
中生北控BioSino是哪个国家的品牌?「中生北控BioSino」是 中生北控生物科技股份有限公司 旗下著名品牌。该品牌发源于北京市,由创始人陈 * 添在1988年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力中生北控BioSino品牌出海!将品牌入驻外推网,定制中生北控BioSino品牌推广信息,可以显著提高中生北控BioSino产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中生北控BioSino怎么样

二十世纪七十年代初,中国科学院生物物理研究所主持承担国家824任务,成功的人工合成了酵母丙氨酸转移核糖核酸。为此,生物物理研究所科技人员组建了工具酶研制组,作为国内生命科学领域高水平的研究基地之一,这只科研队伍研制并生产出主要性能指标达到国外同类水平的酶法临床化学检验试剂。随着科研成果转化规模的不断扩大,为满足市场的迫切需要,生物物理所投资成立了中生生化试剂技术开发公司,就此拉开中国生化诊断试剂产业发展的序幕。经过四十五年的成长与蜕变,成为今天的中生北控生物科技股份有限公司。

中生北控生物科技股份有限公司是中国科学院生物物理研究所创办并控股的高新技术企业,以蛋白质产业为主业,主要从事体外诊断产品的研发、生产和销售。自1973年建厂到1988年公司成立以来,始终以满足民生需求为导向,积极推动民族IVD产业的发展,打造产、学、研、用相结合的自主创新体系,探索“国际化、集团化、复合化”的经营模式,构建“系统化、系列化、整体化、智能化”四化一体的全产业链,提升核心竞争力,在行业中处于重要地位。

中生北控公司自研发和生产“酶法诊断单、双试剂”系列产品以来,经过四十五年的发展,建立了完整的生化检测系列产品平台,发展了免疫诊断系列产品、分子诊断系列产品、血球诊断系列产品、医用临床营养诊断系列产品等。公司拥有包括由8位博士、33位硕士组成的能力过硬的科研团队,拥有由国家人事部批准设立的“企业博士后科研工作站”,与国内生命科学领域高水平的科研机构联建的体外诊断工程研究中心,并与国际知名企业开展合作。

中生北控公司根植于中国科学院这片知识创新的沃土,秉承“做诚信人、为天下先”的企业价值观,拥有16000平方米严格按照GMP标准建设的生产基地,产品质量通过了ISO13485体系认证,质量管理和质量控制水平通过ISO/ICE17025:2005《检验与校准实验室能力的通用要求》的认可,获得使用CNAS实验室认可标志。公司在国内拥有500多家代理商和销售商,在全国大部分的省份和海外都设有分支机构,建立了覆盖全国的市场营销网络及技术支持与技术服务体系。



In the early 1970s, the Institute of Biophysics, Chinese Academy of Sciences, took charge of the national 824 task and successfully synthesized yeast alanine tRNA. For this reason, the scientific and technological personnel of the Institute of Biophysics have set up a tool enzyme research group, which is one of the high-level research bases in the field of life science in China. This research team has developed and produced the enzyme clinical chemical test reagents whose main performance indexes reach the same level in foreign countries. With the continuous expansion of the transformation scale of scientific research achievements, in order to meet the urgent needs of the market, the Institute of biophysics has invested in the establishment of the Zhongsheng biochemical reagent technology development company, which has opened the prelude to the development of China's biochemical diagnostic reagent industry. After 45 years of growth and transformation, it has become today's Zhongsheng Beikong Biotechnology Co., Ltd. Zhongsheng Beikong Biotechnology Co., Ltd. is a high-tech enterprise established and controlled by the Institute of Biophysics, Chinese Academy of Sciences. Its main business is protein industry, mainly engaged in the research, development, production and sales of in vitro diagnostic products. Since its establishment in 1973 and its establishment in 1988, the company has always been oriented to meet the needs of the people's livelihood, actively promoting the development of national IVD industry, building an independent innovation system combining production, learning, research and use, exploring the business model of "internationalization, collectivization and compounding", building a whole industrial chain of "systematization, seriation, integration and intelligence", and improving the core Competitiveness, in the industry in an important position. Since the R & D and production of "enzyme diagnosis single and double reagents" series products, after 45 years of development, the company has established a complete biochemical detection series product platform, developed immune diagnosis series products, molecular diagnosis series products, blood cell diagnosis series products, medical clinical nutrition diagnosis series products, etc. The company has an excellent research team composed of 8 doctors and 33 masters, an "enterprise postdoctoral research workstation" approved by the Ministry of human resources of the people's Republic of China, an in vitro diagnostic engineering research center jointly established with domestic high-level scientific research institutions in the field of life sciences, and cooperates with internationally renowned enterprises. Zhongsheng Beikong company is rooted in the fertile land of knowledge innovation of the Chinese Academy of Sciences. It adheres to the enterprise values of "being honest, being the first in the world". It has a 16000 square meter production base built in strict accordance with GMP standards. Its product quality has passed the ISO13485 system certification. Its quality management and quality control level have passed the general requirements for the ability of inspection and calibration laboratories (ISO / ice17025:2005) The CNAs laboratory approval mark is obtained. The company has more than 500 agents and distributors in China, branches in most provinces and overseas, and established a nationwide marketing network, technical support and technical service system.

本文链接: https://brand.waitui.com/20a181997.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

东芯股份:上海砺算产品并非应用于大模型算力集群等相关场景

36氪获悉,东芯股份公告,公司股价累计涨幅较大,超过大部分同行业公司股价涨幅及上证指数涨幅,可能存在短期上涨过快出现的下跌风险。公司对外投资企业上海砺算的相关芯片产品主要应用于个人电脑、专业设计、AIPC、云游戏、云渲染、数字孪生等场景,并非应用于大模型算力集群等相关场景,尚需要经过客户端产品认证、客户导入等环节。标的公司仍然存在产业化进度风险、市场竞争与业绩风险、持续经营风险等相关风险,敬请投资者谨慎决策,理性对待市场热点概念,注意投资风险。

2小时前

贵州茅台回应“联营公司计划暂停”

有市场消息称,茅台计划推进在各省成立联营公司,各省联营公司注册资金设定在5000万元至1亿元区间,由参与经销商共同出资。该联营公司由各省经销商联谊会牵头,主要目的是助力茅台酒市场价格平稳,以及启动本省定制文化产品开发。近一个月来,据多地经销商和知情人士透露出的消息,该公司预计8月10日前完成入股前期准备,并于2025年四季度启动区域文创酒上市。然而,据媒体报道,有经销商称,茅台的省级联营公司推进计划已暂缓,具体原因尚不明朗。 贵州茅台工作人员回应:“从目前信息来看,贵州茅台本身并未参与其中,如果公司要内设机构,肯定会有相关的决策程序。”(界面)

2小时前

美股大型科技股盘前普涨,Meta涨超10%

36氪获悉,美股大型科技股盘前普涨,截至发稿,Meta涨超10%,微软涨超9%,亚马逊、英伟达涨超2%,特斯拉涨0.21%,苹果涨0.16%,谷歌涨0.03%,奈飞跌0.13%。

2小时前

热门中概股美股盘前多数上涨,哔哩哔哩涨超2%

36氪获悉,热门中概股美股盘前多数上涨,截至发稿,哔哩哔哩涨超2%,阿里巴巴涨0.8%,蔚来涨0.67%,百度涨0.62%,理想汽车涨0.11%,小鹏汽车涨0.06%;京东、拼多多跌超1%。

2小时前

微软成为史上第二家市值突破4万亿美元公司

微软开盘涨超8%,成为史上第二家市值突破4万亿美元公司。

2小时前

本页详细列出关于中生北控BioSino的品牌信息,含品牌所属公司介绍,中生北控BioSino所处行业的品牌地位及优势。
咨询